Literature DB >> 16389309

Knock-in mouse models of Huntington's disease.

Liliana B Menalled1.   

Abstract

Huntington's disease is an autosomal dominant neurodegenerative disorder that is characterized by motor, cognitive, and psychiatric alterations. The mutation responsible for this fatal disease is an abnormally expanded and unstable CAG repeat within the coding region of the gene encoding huntingtin. Numerous mouse models have been generated that constitute invaluable tools to examine the pathogenesis of the disease and to develop and evaluate novel therapies. Among those models, knock-in mice provide a genetically precise reproduction of the human condition. The slow progression and early development of behavioral, pathological, cellular, and molecular abnormalities in knock-in mice make these animals valuable to understand the early pathological events triggered by the mutation. This review describes the different knock-in models generated, the insight gained from them, and their value in the development and testing of prospective treatments of the disease.

Entities:  

Mesh:

Year:  2005        PMID: 16389309      PMCID: PMC1144489          DOI: 10.1602/neurorx.2.3.465

Source DB:  PubMed          Journal:  NeuroRx        ISSN: 1545-5343


  65 in total

1.  Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation.

Authors:  R J Carter; L A Lione; T Humby; L Mangiarini; A Mahal; G P Bates; S B Dunnett; A J Morton
Journal:  J Neurosci       Date:  1999-04-15       Impact factor: 6.167

2.  Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease.

Authors:  E Martín-Aparicio; A Yamamoto; F Hernández; R Hen; J Avila; J J Lucas
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

3.  Neurological abnormalities in a knock-in mouse model of Huntington's disease.

Authors:  C H Lin; S Tallaksen-Greene; W M Chien; J A Cearley; W S Jackson; A B Crouse; S Ren; X J Li; R L Albin; P J Detloff
Journal:  Hum Mol Genet       Date:  2001-01-15       Impact factor: 6.150

4.  Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum.

Authors:  L M Mende-Mueller; T Toneff; S R Hwang; M F Chesselet; V Y Hook
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

Review 5.  Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease.

Authors:  J F Gusella; M E MacDonald
Journal:  Nat Rev Neurosci       Date:  2000-11       Impact factor: 34.870

6.  Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice.

Authors:  I Dragatsis; M S Levine; S Zeitlin
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

7.  Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease?

Authors:  L Kennedy; P F Shelbourne
Journal:  Hum Mol Genet       Date:  2000-10-12       Impact factor: 6.150

8.  Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice.

Authors:  H Li; S H Li; Z X Yu; P Shelbourne; X J Li
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

9.  Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis.

Authors:  E Sapp; P Ge; H Aizawa; E Bird; J Penney; A B Young; J P Vonsattel; M DiFiglia
Journal:  Neuroscience       Date:  1995-01       Impact factor: 3.590

10.  Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease.

Authors:  C Zuccato; A Ciammola; D Rigamonti; B R Leavitt; D Goffredo; L Conti; M E MacDonald; R M Friedlander; V Silani; M R Hayden; T Timmusk; S Sipione; E Cattaneo
Journal:  Science       Date:  2001-06-14       Impact factor: 47.728

View more
  59 in total

1.  Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease.

Authors:  Kuan-Yu Liu; Yu-Chiau Shyu; Brett A Barbaro; Yuan-Ta Lin; Yijuang Chern; Leslie Michels Thompson; Che-Kun James Shen; J Lawrence Marsh
Journal:  Hum Mol Genet       Date:  2014-11-14       Impact factor: 6.150

Review 2.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

3.  Genetic interaction between expanded murine Hdh alleles and p53 reveal deleterious effects of p53 on Huntington's disease pathogenesis.

Authors:  Amy B Ryan; Scott O Zeitlin; Heidi Scrable
Journal:  Neurobiol Dis       Date:  2006-09-15       Impact factor: 5.996

4.  Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice.

Authors:  M A Hickey; A Kosmalska; J Enayati; R Cohen; S Zeitlin; M S Levine; M-F Chesselet
Journal:  Neuroscience       Date:  2008-08-27       Impact factor: 3.590

5.  A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.

Authors:  Danielle A Simmons; Nadia P Belichenko; Tao Yang; Christina Condon; Marie Monbureau; Mehrdad Shamloo; Deqiang Jing; Stephen M Massa; Frank M Longo
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

6.  The Novel Alpha-2 Adrenoceptor Inhibitor Beditin Reduces Cytotoxicity and Huntingtin Aggregates in Cell Models of Huntington's Disease.

Authors:  Elisabeth Singer; Lilit Hunanyan; Magda M Melkonyan; Jonasz J Weber; Lusine Danielyan; Huu Phuc Nguyen
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-12

Review 7.  Animal models for metabolic, neuromuscular and ophthalmological rare diseases.

Authors:  Guillaume Vaquer; Frida Rivière; Maria Mavris; Fabrizia Bignami; Jordi Llinares-Garcia; Kerstin Westermark; Bruno Sepodes
Journal:  Nat Rev Drug Discov       Date:  2013-03-15       Impact factor: 84.694

8.  Force-plate quantification of progressive behavioral deficits in the R6/2 mouse model of Huntington's disease.

Authors:  Stephen C Fowler; Benjamin R Miller; Thomas W Gaither; Michael A Johnson; George V Rebec
Journal:  Behav Brain Res       Date:  2009-03-28       Impact factor: 3.332

9.  Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease.

Authors:  Qian Ma; Jianmin Yang; Thomas Li; Teresa A Milner; Barbara L Hempstead
Journal:  Neurobiol Dis       Date:  2015-08-15       Impact factor: 5.996

10.  Huntingtin facilitates polycomb repressive complex 2.

Authors:  Ihn Sik Seong; Juliana M Woda; Ji-Joon Song; Alejandro Lloret; Priyanka D Abeyrathne; Caroline J Woo; Gillian Gregory; Jong-Min Lee; Vanessa C Wheeler; Thomas Walz; Robert E Kingston; James F Gusella; Ronald A Conlon; Marcy E MacDonald
Journal:  Hum Mol Genet       Date:  2009-11-23       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.